• 1
    Hakomori, S., Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001. 491: 369402.
  • 2
    Ritter, G. and Livingston, P. O., Ganglioside antigens expressed by human cancer cells. Semin. Cancer Biol. 1991. 2: 401409.
  • 3
    Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O. and Livingston, P. O., Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 1997. 73: 4249.
  • 4
    Schulz, G., Cheresh, D. A., Varki, N. M., Yu, A., Staffileno, L. K. and Reisfeld, R. A., Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 1984. 44: 59145920.
  • 5
    Cheung, N. K., Saarinen, U. M., Neely, J. E., Landmeier, B., Donovan, D. and Coccia, P. F., Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985. 45: 26422649.
  • 6
    Xiao, W. H., Yu, A. L. and Sorkin, L. S., Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 1997. 69: 145151.
  • 7
    Cheresh, D. A., Harper, J. R., Schulz, G. and Reisfeld, R. A., Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc. Natl. Acad. Sci. USA 1984. 81: 57675771.
  • 8
    Cheresh, D. A., Rosenberg, J., Mujoo, K., Hirschowitz, L. and Reisfeld, R. A., Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res. 1986. 46: 51125118.
  • 9
    Saito, M., Yu, R. K. and Cheung, N. K., Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell. Biochem. Biophys. Res. Commun. 1985. 127: 17.
  • 10
    Cheung, N. K., Kushner, B. H., Cheung, I. Y., Kramer, K., Canete, A., Gerald, W., Bonilla, M. A. et al., Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J. Clin. Oncol. 1998. 16: 30533060.
  • 11
    Kramer, K., Gerald, W. L., Kushner, B. H., Larson, S. M., Hameed, M. and Cheung, N. K., Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma. Med. Pediatr. Oncol. 2001. 36: 194196.
  • 12
    Mujoo, K., Cheresh, D. A., Yang, H. M. and Reisfeld, R. A., Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987. 47: 10981104.
  • 13
    Mueller, B. M., Romerdahl, C. A., Gillies, S. D. and Reisfeld, R. A., Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J. Immunol. 1990. 144: 13821386.
  • 14
    Kendra, K., Malkovska, V., Allen, M., Guzman, J. and Albertini, M., In vivo binding and antitumor activity of ch14.18. J. Immunother. 1999. 22: 423430.
  • 15
    Raffaghello, L., Marimpietri, D., Pagnan, G., Pastorino, F., Cosimo, E., Brignole, C., Ponzoni, M. and Montaldo, P. G., Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Lett. 2003. 197: 205209.
  • 16
    Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Allen, L., Tilden, A. B., Grizzle, W., Reisfeld, R. A. et al., Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum. Antibodies Hybridomas 1992. 3: 1924.
  • 17
    Handgretinger, R., Anderson, K., Lang, P., Dopfer, R., Klingebiel, T., Schrappe, M., Reuland, P. et al., A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur. J. Cancer 1995. 31A: 261267.
  • 18
    Yu, A. L., Uttenreuther-Fischer, M. M., Huang, C. S., Tsui, C. C., Gillies, S. D., Reisfeld, R. A. and Kung, F. H., Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 1998. 16: 21692180.
  • 19
    Murray, J. L., Kleinerman, E. S., Jia, S. F., Rosenblum, M. G., Eton, O., Buzaid, A., Legha, S. et al., Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J. Immunother. Emphasis Tumor Immunol. 1996. 19: 206217.
  • 20
    Ozkaynak, M. F., Sondel, P. M., Krailo, M. D., Gan, J., Javorsky, B., Reisfeld, R. A., Matthay, K. K. et al., Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J. Clin. Oncol. 2000. 18: 40774085.
  • 21
    Albertini, M. R., Hank, J. A., Schiller, J. H., Khorsand, M., Borchert, A. A., Gan, J., Bechhofer, R. et al., Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res. 1997. 3: 12771288.
  • 22
    Lode, H. N., Xiang, R., Varki, N. M., Dolman, C. S., Gillies, S. D. and Reisfeld, R. A., Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 1997. 89: 15861594.
  • 23
    King, D. M., Albertini, M. R., Schalch, H., Hank, J. A., Gan, J., Surfus, J., Mahvi, D. et al., Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J. Clin. Oncol. 2004. 22: 44634473.
  • 24
    Zhang, H., Zhang, S., Cheung, N. K., Ragupathi, G. and Livingston, P. O., Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. 1998. 58: 28442849.
  • 25
    Förster-Waldl, E., Riemer, A. B., Dehof, A. K., Neumann, D., Bramswig, K., Boltz-Nitulescu, G., Pehamberger, H. et al., Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol. 2005. 42: 319325.
  • 26
    Saleh, M. N., Stapleton, J. D., Khazaeli, M. B. and LoBuglio, A. F., Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. J. Immunol. 1993. 151: 33903398.
  • 27
    Foon, K. A., Sen, G., Hutchins, L., Kashala, O. L., Baral, R., Banerjee, M., Chakraborty, M. et al., Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin. Cancer Res. 1998. 4: 11171124.
  • 28
    Basak, S., Birebent, B., Purev, E., Somasundaram, R., Maruyama, H., Zaloudik, J., Swoboda, R. et al., Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer. Immunol. Immunother. 2003. 52: 145154.
  • 29
    Livingston, P. O., Ritter, G. and Calves, M. J., Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol. Immunother. 1989. 29: 179184.
  • 30
    Portoukalian, J., Carrel, S., Dore, J. F. and Rumke, P., Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group. Int. J. Cancer 1991. 49: 893899.
  • 31
    Ragupathi, G., Livingston, P. O., Hood, C., Gathuru, J., Krown, S. E., Chapman, P. B., Wolchok, J. D. et al., Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin. Cancer Res. 2003. 9: 52145220.
  • 32
    Foon, K. A., Lutzky, J., Baral, R. N., Yannelli, J. R., Hutchins, L., Teitelbaum, A., Kashala, O. L. et al., Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol. 2000. 18: 376384.
  • 33
    Scott, J. K. and Smith, G. P., Searching for peptide ligands with an epitope library. Science 1990. 249: 386390.
  • 34
    Oldenburg, K. R., Loganathan, D., Goldstein, I. J., Schultz, P. G. and Gallop, M. A., Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc. Natl. Acad. Sci. USA 1992. 89: 53935397.
  • 35
    Hoess, R., Brinkmann, U., Handel, T. and Pastan, I., Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. Gene 1993. 128: 4349.
  • 36
    Phalipon, A., Folgori, A., Arondel, J., Sgaramella, G., Fortugno, P., Cortese, R., Sansonetti, P. J. and Felici, F., Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur. J. Immunol. 1997. 27: 26202625.
  • 37
    Parmley, S. F. and Smith, G. P., Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene 1988. 73: 305318.
  • 38
    Riemer, A. B., Klinger, M., Wagner, S., Bernhaus, A., Mazzucchelli, L., Pehamberger, H., Scheiner, O. et al., Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol. 2004. 173: 394401.
  • 39
    Riemer, A. B., Hantusch, B., Sponer, B., Kraml, G., Hafner, C., Zielinski, C. C., Scheiner, O. et al., High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol. Immunother. 2005. 54: 677684.
  • 40
    Kieber-Emmons, T., Luo, P., Qiu, J., Agadjanyan, M., Carey, L., Hutchins, W., Westerink, M. A. and Steplewski, Z., Peptide mimicry of adenocarcinoma-associated carbohydrate antigens. Hybridoma 1997. 16: 310.
  • 41
    Kieber-Emmons, T., Luo, P., Qiu, J., Chang, T. Y., O, I., Blaszczyk-Thurin, M. and Steplewski, Z., Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat. Biotechnol. 1999. 17: 660665.
  • 42
    Monzavi-Karbassi, B., Cunto-Amesty, G., Luo, P. and Kieber-Emmons, T., Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery. Trends Biotechnol. 2002. 20: 207214.
  • 43
    Hou, Y. and Gu, X. X., Development of peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccine candidates. J. Immunol. 2003. 170: 43734379.
  • 44
    Kieber-Emmons, T., Monzavi-Karbassi, B., Wang, B., Luo, P. and Weiner, D. B., Cutting edge: DNA immunization with minigenes of carbohydrate mimotopes induce functional anti-carbohydrate antibody response. J. Immunol. 2000. 165: 623627.
  • 45
    Bolesta, E., Kowalczyk, A., Wierzbicki, A., Rotkiewicz, P., Bambach, B., Tsao, C. Y., Horwacik, I. et al., DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 2005. 65: 34103418.